Researchers have been excited about the medication , a novel dual agonist showing significant outcomes in clinical trials for weight reduction . It acts by impacting two pathways : GLP-1 and GIP, which , https://zakariaasbb716928.dgbloggers.com/41194193/the-new-possibility-for-body-management